Concepts (121)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ataxia | 3 | 2017 | 23 | 1.600 |
Why?
|
| Mobility Limitation | 3 | 2017 | 49 | 1.520 |
Why?
|
| Aging | 3 | 2017 | 745 | 1.060 |
Why?
|
| Accidental Falls | 2 | 2017 | 127 | 0.970 |
Why?
|
| Gait | 2 | 2017 | 119 | 0.960 |
Why?
|
| Malaria Vaccines | 5 | 2024 | 37 | 0.880 |
Why?
|
| Malaria, Falciparum | 5 | 2024 | 220 | 0.720 |
Why?
|
| Geriatric Assessment | 2 | 2017 | 163 | 0.620 |
Why?
|
| Postural Balance | 2 | 2017 | 65 | 0.600 |
Why?
|
| Plasmodium falciparum | 7 | 2024 | 246 | 0.540 |
Why?
|
| Mexican Americans | 1 | 2016 | 14 | 0.520 |
Why?
|
| Fear | 1 | 2016 | 70 | 0.500 |
Why?
|
| Communication Barriers | 1 | 2016 | 67 | 0.490 |
Why?
|
| Motor Activity | 2 | 2015 | 346 | 0.440 |
Why?
|
| Life Style | 1 | 2016 | 311 | 0.440 |
Why?
|
| Periodicity | 1 | 2013 | 49 | 0.420 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2024 | 770 | 0.420 |
Why?
|
| Health Behavior | 1 | 2016 | 469 | 0.390 |
Why?
|
| Psychomotor Performance | 1 | 2013 | 137 | 0.390 |
Why?
|
| Antimalarials | 2 | 2019 | 124 | 0.280 |
Why?
|
| Malaria | 3 | 2023 | 148 | 0.260 |
Why?
|
| Cross-Sectional Studies | 3 | 2017 | 2576 | 0.240 |
Why?
|
| Vaccines, Attenuated | 2 | 2023 | 36 | 0.230 |
Why?
|
| Liver | 2 | 2021 | 855 | 0.220 |
Why?
|
| Risk Factors | 3 | 2017 | 5353 | 0.200 |
Why?
|
| Crosses, Genetic | 2 | 2019 | 110 | 0.200 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 5456 | 0.190 |
Why?
|
| Cancer Survivors | 1 | 2024 | 115 | 0.190 |
Why?
|
| Protozoan Proteins | 2 | 2019 | 126 | 0.180 |
Why?
|
| Female | 10 | 2023 | 32871 | 0.180 |
Why?
|
| Aged | 5 | 2017 | 14432 | 0.180 |
Why?
|
| Drug Resistance | 2 | 2019 | 149 | 0.180 |
Why?
|
| Male | 9 | 2021 | 29893 | 0.180 |
Why?
|
| Antibodies, Protozoan | 2 | 2024 | 52 | 0.180 |
Why?
|
| Immunogenicity, Vaccine | 2 | 2020 | 17 | 0.170 |
Why?
|
| Humans | 14 | 2024 | 63429 | 0.160 |
Why?
|
| Chloroquine | 1 | 2019 | 61 | 0.160 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 209 | 0.160 |
Why?
|
| Plasmodium vivax | 1 | 2019 | 46 | 0.150 |
Why?
|
| Membrane Transport Proteins | 1 | 2019 | 135 | 0.150 |
Why?
|
| Artemisinins | 1 | 2018 | 38 | 0.150 |
Why?
|
| Intelligence Tests | 1 | 2017 | 26 | 0.140 |
Why?
|
| Extremities | 1 | 2017 | 44 | 0.130 |
Why?
|
| Independent Living | 1 | 2017 | 51 | 0.130 |
Why?
|
| Preventive Health Services | 1 | 2017 | 75 | 0.130 |
Why?
|
| Statistics as Topic | 1 | 2017 | 147 | 0.130 |
Why?
|
| HIV Infections | 1 | 2024 | 969 | 0.130 |
Why?
|
| Sporozoites | 3 | 2023 | 7 | 0.130 |
Why?
|
| Parasitemia | 1 | 2016 | 47 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2017 | 768 | 0.120 |
Why?
|
| Boston | 1 | 2016 | 252 | 0.120 |
Why?
|
| Linear Models | 1 | 2016 | 410 | 0.120 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 291 | 0.110 |
Why?
|
| Logistic Models | 1 | 2017 | 1277 | 0.110 |
Why?
|
| Exercise | 2 | 2024 | 941 | 0.110 |
Why?
|
| Normal Distribution | 1 | 2013 | 17 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 937 | 0.110 |
Why?
|
| Elbow Joint | 1 | 2013 | 15 | 0.110 |
Why?
|
| Fingers | 1 | 2013 | 46 | 0.100 |
Why?
|
| Body Mass Index | 1 | 2017 | 866 | 0.100 |
Why?
|
| Neoplasms | 1 | 2024 | 1362 | 0.100 |
Why?
|
| Disease Progression | 1 | 2017 | 1171 | 0.100 |
Why?
|
| Movement | 1 | 2013 | 156 | 0.100 |
Why?
|
| Comorbidity | 1 | 2016 | 1123 | 0.100 |
Why?
|
| Diet | 1 | 2016 | 526 | 0.100 |
Why?
|
| Muscle Contraction | 1 | 2013 | 202 | 0.100 |
Why?
|
| Adult | 6 | 2024 | 16822 | 0.090 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 678 | 0.090 |
Why?
|
| Smoking | 1 | 2016 | 866 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2017 | 2569 | 0.090 |
Why?
|
| Stress, Psychological | 1 | 2015 | 469 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2017 | 2079 | 0.080 |
Why?
|
| Vaccination | 3 | 2021 | 363 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2017 | 3290 | 0.080 |
Why?
|
| Animals | 7 | 2023 | 20638 | 0.070 |
Why?
|
| Algorithms | 1 | 2013 | 1001 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2021 | 454 | 0.070 |
Why?
|
| Immunoglobulin G | 2 | 2021 | 459 | 0.070 |
Why?
|
| United States | 1 | 2017 | 7841 | 0.050 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 1007 | 0.050 |
Why?
|
| HIV Seronegativity | 1 | 2024 | 19 | 0.050 |
Why?
|
| Tanzania | 1 | 2024 | 37 | 0.050 |
Why?
|
| HIV Seropositivity | 1 | 2024 | 84 | 0.050 |
Why?
|
| Immunization | 1 | 2023 | 133 | 0.050 |
Why?
|
| Exercise Therapy | 1 | 2024 | 104 | 0.050 |
Why?
|
| Onchocerciasis | 1 | 2002 | 2 | 0.050 |
Why?
|
| Onchocerca volvulus | 1 | 2002 | 3 | 0.050 |
Why?
|
| Middle Aged | 4 | 2024 | 17598 | 0.050 |
Why?
|
| Child | 2 | 2023 | 4533 | 0.050 |
Why?
|
| Protozoan Vaccines | 1 | 2002 | 14 | 0.050 |
Why?
|
| Life Cycle Stages | 1 | 2021 | 17 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2021 | 114 | 0.040 |
Why?
|
| Time Factors | 2 | 2021 | 3767 | 0.040 |
Why?
|
| Kenya | 1 | 2020 | 92 | 0.040 |
Why?
|
| Young Adult | 2 | 2024 | 4692 | 0.040 |
Why?
|
| Genes, Protozoan | 1 | 2019 | 14 | 0.040 |
Why?
|
| Culicidae | 1 | 2019 | 12 | 0.040 |
Why?
|
| Anopheles | 1 | 2019 | 21 | 0.040 |
Why?
|
| Adolescent | 2 | 2024 | 6250 | 0.040 |
Why?
|
| Malaria, Vivax | 1 | 2019 | 48 | 0.040 |
Why?
|
| Aotidae | 1 | 2018 | 11 | 0.040 |
Why?
|
| Drug Discovery | 1 | 2019 | 95 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2020 | 739 | 0.040 |
Why?
|
| Quality of Life | 1 | 2024 | 1228 | 0.030 |
Why?
|
| Gene Expression | 1 | 2019 | 840 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2016 | 74 | 0.030 |
Why?
|
| Pregnancy | 1 | 2023 | 2336 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 66 | 0.030 |
Why?
|
| Infant | 1 | 2020 | 1650 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2016 | 256 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 1997 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2016 | 567 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 777 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2015 | 753 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 1616 | 0.020 |
Why?
|
| Mutation | 1 | 2018 | 2608 | 0.020 |
Why?
|
| Vaccines, Synthetic | 1 | 2002 | 78 | 0.010 |
Why?
|
| Antigens, Protozoan | 1 | 2002 | 56 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2002 | 517 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 1330 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 1991 | 0.010 |
Why?
|